Sanofi to enroll thousands for its coronavirus vaccine trials | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
October 02, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, OCTOBER 02, 2023
Sanofi to enroll thousands for its coronavirus vaccine trials

Coronavirus chronicle

Reuters
06 May, 2020, 03:20 pm
Last modified: 06 May, 2020, 05:50 pm

Related News

  • Govt looks to regain economy's pre-Covid momentum by the end of current fiscal
  • New Zealand PM tests positive for Covid-19, to work via zoom
  • Long Covid linked to multiple organ changes, research suggests
  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House

Sanofi to enroll thousands for its coronavirus vaccine trials

Sanofi is working on two vaccine projects to prevent Covid-19 - the illness caused by the new coronavirus - and said it is exploring several manufacturing options

Reuters
06 May, 2020, 03:20 pm
Last modified: 06 May, 2020, 05:50 pm
A man wearing a protective face mask walks past the logo of Sanofi at the company's headquarters in Paris, France, April 24, 2020/ Reuters
A man wearing a protective face mask walks past the logo of Sanofi at the company's headquarters in Paris, France, April 24, 2020/ Reuters

French drugmaker Sanofi SA said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline Plc, and that it has started to discuss advanced purchases with several countries.

Sanofi is working on two vaccine projects to prevent Covid-19 - the illness caused by the new coronavirus - and said it is exploring several manufacturing options, including fresh collaborations to ensure it can meet demand, if either program is successful.

Drugmakers are rushing to develop treatments and vaccines for the highly contagious coronavirus that has killed over 255,000 people worldwide, infected more than 3.6 million and ravaged economies globally.

Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far, according to California-based think tank Milken Institute.

Sanofi, whose Pasteur division has an established track record in influenza vaccines, teamed with British rival GSK last month to come up with a candidate it hopes will be ready next year.

Sanofi will bring in a protein antigen - a molecule designed to trigger an immune response in the body - based on a platform it uses for its influenza vaccine Flublok.

GSK will contribute one of its approved adjuvants, which work by boosting the immune response to produce more antibodies and longer-lasting immunity.

Sanofi Pasteur executives told Reuters the company hopes to start early-stage trials in September, with hundreds of subjects enrolled.

While Phase I vaccine trials typically involves a small number of healthy volunteers to test for safety, Sanofi said it had opted for higher numbers to secure stronger data sooner.

"We envisioned Phase I to actually have several hundreds of subjects, so it is really a phase I/II trial," said John Shiver, head of Sanofi vaccine research.

Beyond finding the right vaccine, a key challenge lies in manufacturing on an enormous scale and distributing the product globally.

"We will be comparing different doses of the vaccine and that is very critical. It will tell us about the factory capacity and what we need to do to produce the number of doses that we projected," Shiver said.

Sanofi previously said it will be able to produce over a billion doses. Its project with GSK has received financial support from the Biomedical Advanced Research and Development Authority (BARDA) of the US Health Department.

Late-stage trials with thousands of subjects comparing the vaccine to placebo are expected to take place by year-end or early 2021, Shiver said, adding that some previous Sanofi influenza trials had enrolled up to 30,000 participants.

A Bit 'Tricky'

David Loew, executive vice president for vaccines, said Sanofi has begun preliminary discussions with countries over mechanisms for pre-ordering the vaccine, if it works, although legal details must still be worked out with GSK.

"It is a bit of a tricky thing when you partner with another company," he said, adding that talks were taking place with US officials as well as with some European countries.

Given the support from BARDA, doses produced at its US manufacturing facility are expected to go to US patients first, a prospect that has raised concern in Europe.

Asked if Sanofi would consider new collaborations to ensure it can deliver on its manufacturing pledges, Loew said, "yes, if we come to the conclusion that we do not have enough capacity."

Sanofi Chief Executive Paul Hudson on April 24 urged stronger European coordination in the hunt for a vaccine against the new coronavirus, criticising Europe for being too slow.

Sanofi is also working with US-based Translate Bio Inc on another vaccine candidate based on messenger RNA technology, similar to experimental vaccines being developed by Pfizer Inc in partnership with BioNTech SE and another Moderna Inc is developing in partnership with the US government.

The mRNA technology instructs cells in the body to make specific coronavirus proteins that then produce an immune response. Trials of that vaccine are expected to start in the fourth quarter.

Top News

Biomedical Advanced Research and Development Authority (BARDA) / Sanofi / Coronavirus Vaccine / Vaccine trail / Coronavirus / Coronavirus treatment / fighting coronavirus / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Illustration: TBS
    Why do Bangladeshi universities fare so poorly in global rankings?
  • Big drops in remittance, exports make reserves struggle harsher
    Big drops in remittance, exports make reserves struggle harsher
  • Shahjahan Bhuiyan’s parents and two out of his three siblings passed away when he was behind bars. He missed all the funerals.  
Photo: Nayem Ali
    Hangman Shahjahan Bhuiyan: Life after 60 executions and 44 years in prison

MOST VIEWED

  • Paperfly aborts flight
    Paperfly aborts flight
  • Photo: TBS
    Habibur Rahman takes charge as 36th DMP commissioner
  • Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
    Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
  • How China's Belt and Road changing Bangladesh's  infrastructures
    How China's Belt and Road changing Bangladesh's infrastructures
  • Photo: TBS
    Dhaka traffic slowest in world: Study
  • US dollar banknotes are seen in this illustration taken on 10 March 2023. Photo: Reuters
    Remittance earnings in September lowest in 41 months

Related News

  • Govt looks to regain economy's pre-Covid momentum by the end of current fiscal
  • New Zealand PM tests positive for Covid-19, to work via zoom
  • Long Covid linked to multiple organ changes, research suggests
  • Covid-19 economic impact lingers on in parts of society: Study
  • Jill Biden positive for Covid, President Biden tests negative: White House

Features

Shahjahan Bhuiyan’s parents and two out of his three siblings passed away when he was behind bars. He missed all the funerals.  
Photo: Nayem Ali

Hangman Shahjahan Bhuiyan: Life after 60 executions and 44 years in prison

1h | Panorama
Illustration: Collected

Apology to a life forgotten to live

15h | Features
Photo: Kazi Ashraf Uddin

Coffee: More than a beverage, something of a beloved

18h | Features
The price back to the normal range is possible if the corporations who control the feed market reduce the feed and chick prices. Photo: Noor-A-Alam

Will eggs ever return to their 'normal' price?

21h | Features

More Videos from TBS

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

12h | TBS SPORTS
Apple is bringing new software updates to prevent overheating

Apple is bringing new software updates to prevent overheating

14h | Tech Talk
A unique study cafe in the city

A unique study cafe in the city

13h | TBS Stories
Reserves are falling even as the dollar's share of global payments rises

Reserves are falling even as the dollar's share of global payments rises

17h | TBS Economy
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]